{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:24:48Z","timestamp":1759742688682},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T00:00:00Z","timestamp":1539388800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Il viaggio di Paolo"},{"name":"Gruppo Italiano Mesotelioma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12967-018-1650-0","type":"journal-article","created":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T05:18:55Z","timestamp":1539407935000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification"],"prefix":"10.1186","volume":"16","author":[{"given":"Kun","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emyr","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Guazzelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasen","family":"Alhebshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Meysami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Demonacos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Krstic-Demonacos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,13]]},"reference":[{"issue":"3","key":"1650_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","volume":"35","author":"A Scherpereel","year":"2010","unstructured":"Scherpereel A, et al. Guidelines of the European respiratory society and the European society of thoracic surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479\u201395.","journal-title":"Eur Respir J"},{"issue":"8","key":"1650_CR2","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/13543784.2017.1351545","volume":"26","author":"A Guazzelli","year":"2017","unstructured":"Guazzelli A, et al. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Expert Opin Investig Drugs. 2017;26(8):933\u201344.","journal-title":"Expert Opin Investig Drugs"},{"issue":"142","key":"1650_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/16000617.0063-2016","volume":"25","author":"AC Bibby","year":"2016","unstructured":"Bibby AC, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472\u201386.","journal-title":"Eur Respir Rev"},{"key":"1650_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407.","journal-title":"Nat Genet"},{"issue":"3","key":"1650_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","volume":"13","author":"J Jongsma","year":"2008","unstructured":"Jongsma J, et al. A conditional mouse model for malignant mesothelioma. Cancer Cell. 2008;13(3):261\u201371.","journal-title":"Cancer Cell"},{"issue":"4","key":"1650_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2","volume":"75","author":"JB Prins","year":"1998","unstructured":"Prins JB, et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer. 1998;75(4):649\u201353.","journal-title":"Int J Cancer"},{"issue":"11\u201312","key":"1650_CR7","first-page":"340","volume":"7","author":"N Nabavi","year":"2016","unstructured":"Nabavi N, et al. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes Cancer. 2016;7(11\u201312):340\u201354.","journal-title":"Genes Cancer"},{"issue":"3","key":"1650_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","volume":"18","author":"M Carbone","year":"2012","unstructured":"Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 2012;18(3):598\u2013604.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1650_CR9","first-page":"5547","volume":"54","author":"JQ Cheng","year":"1994","unstructured":"Cheng JQ, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Can Res. 1994;54(21):5547\u201351.","journal-title":"Can Res"},{"issue":"5","key":"1650_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9(5):338\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1650_CR11","doi-asserted-by":"publisher","first-page":"e72303","DOI":"10.1371\/journal.pone.0072303","volume":"8","author":"K Tian","year":"2013","unstructured":"Tian K, et al. Dynamics of DNA damage induced pathways to cancer. PLoS ONE. 2013;8(9):e72303.","journal-title":"PLoS ONE"},{"issue":"11","key":"1650_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1039\/c2ib20193c","volume":"4","author":"ML Wynn","year":"2012","unstructured":"Wynn ML, et al. Logic-based models in systems biology: a predictive and parameter-free network analysis method. Integr Biol. 2012;4(11):1323\u201337.","journal-title":"Integr Biol"},{"issue":"11","key":"1650_CR13","doi-asserted-by":"publisher","first-page":"e1005825","DOI":"10.1371\/journal.pcbi.1005825","volume":"13","author":"E Bakker","year":"2017","unstructured":"Bakker E, et al. Insight into glucocorticoid receptor signalling through interactome model analysis. PLoS Comput Biol. 2017;13(11):e1005825.","journal-title":"PLoS Comput Biol"},{"key":"1650_CR14","unstructured":"Hussain M, et al. Applications of p53 interactome analysis to personalised drug discovery. In: International work-conference on bioinformatics and biomedical engineering (IWBBIO 2014). 2014. Universidad de Granada, Granada, Spain."},{"issue":"25","key":"1650_CR15","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1038\/onc.2012.321","volume":"32","author":"DW Chen","year":"2013","unstructured":"Chen DW, et al. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia. Oncogene. 2013;32(25):3039\u201348.","journal-title":"Oncogene"},{"issue":"5","key":"1650_CR16","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1182\/blood-2005-07-2853","volume":"107","author":"S Schmidt","year":"2006","unstructured":"Schmidt S, et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood. 2006;107(5):2061\u20139.","journal-title":"Blood"},{"issue":"1","key":"1650_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/thx.2007.093872","volume":"64","author":"SM Lee","year":"2009","unstructured":"Lee SM, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax. 2009;64(1):75\u201380.","journal-title":"Thorax"},{"issue":"9","key":"1650_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/14737140.2017.1358091","volume":"17","author":"E Bakker","year":"2017","unstructured":"Bakker E, et al. Immunotherapy advances for mesothelioma treatment. Expert Rev Anticancer Ther. 2017;17(9):799\u2013814.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"1650_CR19","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","volume":"34","author":"KR Hande","year":"1998","unstructured":"Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34(10):1514\u201321.","journal-title":"Eur J Cancer"},{"issue":"12","key":"1650_CR20","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1039\/c2mb25215e","volume":"8","author":"Z Isik","year":"2012","unstructured":"Isik Z, et al. A signal transduction score flow algorithm for cyclic cellular pathway analysis, which combines transcriptome and ChIP-seq data. Mol BioSyst. 2012;8(12):3224\u201331.","journal-title":"Mol BioSyst"},{"key":"1650_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1752-0509-3-7","volume":"3","author":"TS Christensen","year":"2009","unstructured":"Christensen TS, Oliveira AP, Nielsen J. Reconstruction and logical modeling of glucose repression signaling pathways in Saccharomyces cerevisiae. BMC Syst Biol. 2009;3:7.","journal-title":"BMC Syst Biol"},{"key":"1650_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-biochem-072511-122603","volume":"82","author":"L Balakrishnan","year":"2013","unstructured":"Balakrishnan L, Bambara RA. Flap endonuclease 1. Annu Rev Biochem. 2013;82:119\u201338.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"1650_CR23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/0008-5472.130.65.1","volume":"65","author":"X Xu","year":"2005","unstructured":"Xu X, et al. Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Can Res. 2005;65(1):130\u20136.","journal-title":"Can Res"},{"issue":"9","key":"1650_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1101\/gad.300053.117","volume":"31","author":"L Ji","year":"2017","unstructured":"Ji L, et al. The SIAH E3 ubiquitin ligases promote Wnt\/\u03b2-catenin signaling through mediating Wnt-induced Axin degradation. Genes Dev. 2017;31(9):904\u201315.","journal-title":"Genes Dev"},{"key":"1650_CR25","doi-asserted-by":"publisher","first-page":"e1051","DOI":"10.1038\/cddis.2014.9","volume":"5","author":"I Amelio","year":"2014","unstructured":"Amelio I, et al. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis. 2014;5:e1051.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1650_CR26","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/cancers3010994","volume":"3","author":"T Ozaki","year":"2011","unstructured":"Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers. 2011;3(1):994\u20131013.","journal-title":"Cancers"},{"issue":"4","key":"1650_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4161\/cc.27546","volume":"13","author":"D Marzo Di","year":"2014","unstructured":"Di Marzo D, et al. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle. 2014;13(4):652\u201365.","journal-title":"Cell Cycle"},{"issue":"288","key":"1650_CR28","doi-asserted-by":"publisher","first-page":"ra68","DOI":"10.1126\/scisignal.2004008","volume":"6","author":"DC Kirouac","year":"2013","unstructured":"Kirouac DC, et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2\/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal. 2013;6(288):ra68.","journal-title":"Sci Signal"},{"issue":"7","key":"1650_CR29","doi-asserted-by":"publisher","first-page":"e69008","DOI":"10.1371\/journal.pone.0069008","volume":"8","author":"HF Fumi\u00e3","year":"2013","unstructured":"Fumi\u00e3 HF, Martins ML. Boolean network model for cancer pathways: predicting carcinogenesis and targeted therapy outcomes. PLoS ONE. 2013;8(7):e69008.","journal-title":"PLoS ONE"},{"issue":"4","key":"1650_CR30","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jtbi.2009.04.024","volume":"259","author":"Z Mai","year":"2009","unstructured":"Mai Z, Liu H. Boolean network-based analysis of the apoptosis network: irreversible apoptosis and stable surviving. J Theor Biol. 2009;259(4):760\u20139.","journal-title":"J Theor Biol"},{"issue":"12","key":"1650_CR31","doi-asserted-by":"publisher","first-page":"e1000595","DOI":"10.1371\/journal.pcbi.1000595","volume":"5","author":"R Schlatter","year":"2009","unstructured":"Schlatter R, et al. ON\/OFF and beyond\u2014a Boolean model of apoptosis. PLoS Comput Biol. 2009;5(12):e1000595.","journal-title":"PLoS Comput Biol"},{"key":"1650_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1752-0509-6-125","volume":"6","author":"R Poltz","year":"2012","unstructured":"Poltz R, Naumann M. Dynamics of p53 and NF-kappaB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention. BMC Syst Biol. 2012;6:125.","journal-title":"BMC Syst Biol"},{"issue":"1","key":"1650_CR33","doi-asserted-by":"publisher","first-page":"e970480","DOI":"10.4161\/23723548.2014.970480","volume":"2","author":"A Poppy Roworth","year":"2015","unstructured":"Poppy Roworth A, Ghari F, La Thangue NB. To live or let die\u2014complexity within the E2F1 pathway. Mol Cell Oncol. 2015;2(1):e970480.","journal-title":"Mol Cell Oncol"},{"issue":"12","key":"1650_CR34","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-16-3566","volume":"77","author":"AL Gartel","year":"2017","unstructured":"Gartel AL. FOXM1 in cancer: interactions and vulnerabilities. Can Res. 2017;77(12):3135\u20139.","journal-title":"Can Res"},{"issue":"1","key":"1650_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.trecan.2017.11.002","volume":"4","author":"J Li","year":"2018","unstructured":"Li J, et al. PRC1: linking cytokinesis, chromosomal instability, and cancer evolution. Trends Cancer. 2018;4(1):59\u201373.","journal-title":"Trends Cancer"},{"issue":"1","key":"1650_CR36","doi-asserted-by":"publisher","first-page":"e85935","DOI":"10.1371\/journal.pone.0085935","volume":"9","author":"O Melaiu","year":"2014","unstructured":"Melaiu O, et al. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS ONE. 2014;9(1):e85935.","journal-title":"PLoS ONE"},{"issue":"4","key":"1650_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1073\/pnas.0510146103","volume":"103","author":"Y Liu","year":"2006","unstructured":"Liu Y, Bodmer WF. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci USA. 2006;103(4):976\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"1650_CR38","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/thx.2006.069872","volume":"62","author":"P Bertino","year":"2007","unstructured":"Bertino P, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax. 2007;62(8):690\u20135.","journal-title":"Thorax"},{"key":"1650_CR39","unstructured":"Genomics of Drug Sensitivity in Cancer. Compound: etoposide. n.d. https:\/\/www.cancerrxgene.org\/translation\/Drug\/134 . Accessed 10 May 2018."},{"issue":"8","key":"1650_CR40","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.tiv.2011.05.023","volume":"25","author":"S Martinotti","year":"2011","unstructured":"Martinotti S, Ranzato E, Burlando B. In vitro screening of synergistic ascorbate\u2013drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro. 2011;25(8):1568\u201374.","journal-title":"Toxicol In Vitro"},{"issue":"6","key":"1650_CR41","doi-asserted-by":"publisher","first-page":"e0178606","DOI":"10.1371\/journal.pone.0178606","volume":"12","author":"MY Qattan","year":"2017","unstructured":"Qattan MY, et al. Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia. PLoS ONE. 2017;12(6):e0178606.","journal-title":"PLoS ONE"},{"issue":"2","key":"1650_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/bioinformatics\/19.2.185","volume":"19","author":"BM Bolstad","year":"2003","unstructured":"Bolstad BM, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185\u201393.","journal-title":"Bioinformatics"},{"issue":"7","key":"1650_CR43","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1650_CR44","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim D, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.","journal-title":"Genome Biol"},{"issue":"9","key":"1650_CR45","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","volume":"25","author":"C Trapnell","year":"2009","unstructured":"Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics (Oxford, England). 2009;25(9):1105\u201311.","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"1","key":"1650_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"M Robinson","year":"2010","unstructured":"Robinson M, McCarthy D, Smyth G. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Biofinormatics. 2010;26(1):139\u201340.","journal-title":"Biofinormatics"},{"key":"1650_CR47","unstructured":"Carlson, M. org.Hs.eg.db: genome wide annotation for human. 2017. http:\/\/bioconductor.org\/packages\/release\/data\/annotation\/html\/org.Hs.eg.db.html . Accessed 10 May 2018."},{"issue":"Database issue","key":"1650_CR48","first-page":"D258","volume":"32","author":"MA Harris","year":"2004","unstructured":"Harris MA, et al. The gene ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32(Database issue):D258\u201361.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1650_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nar\/27.1.29","volume":"27","author":"H Ogata","year":"1999","unstructured":"Ogata H, et al. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999;27(1):29\u201334.","journal-title":"Nucleic Acids Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1650-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-018-1650-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1650-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T23:09:25Z","timestamp":1662246565000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-018-1650-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,13]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1186\/s12967-018-1650-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,13]]},"assertion":[{"value":"30 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"282"}}